We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.
- Authors
Dransfield, Mark T; Harnden, Sarah; Burton, Robert L; Albert, Richard K; Bailey, William C; Casaburi, Richard; Connett, John; Cooper, J Allen D; Criner, Gerard J; Curtis, Jeffrey L; Han, Meilan K; Make, Barry; Marchetti, Nathaniel; Martinez, Fernando J; McEvoy, Charlene; Nahm, Moon H; Niewoehner, Dennis E; Porszasz, Janos; Reilly, John; Scanlon, Paul D; Scharf, Steven M; Sciurba, Frank C; Washko, George R; Woodruff, Prescott G; Lazarus, Stephen C; NIH COPD Clinical Research Network
- Abstract
Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healthy persons, randomized controlled trials in chronic obstructive pulmonary disease (COPD) have demonstrated no benefit in the intention-to-treat population. We previously reported that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and induced greater serotype-specific immunoglobulin G (IgG) and functional antibody than did PPSV23 1 month after vaccination. We hypothesized that these advantages would persist at 1 and 2 years.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Vol 55, Issue 5, pe35
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1093/cid/cis513